Telomir Pharmaceuticals (TELO) Cash from Financing Activities (2023 - 2025)
Telomir Pharmaceuticals (TELO) posted Cash from Financing Activities of $1.2 million for Q4 2025, down 84.56% sequentially from $7.5 million in Q3 2025, and up 11.71% YoY from $1.0 million in Q4 2024.
Telomir Pharmaceuticals (TELO) Cash from Financing Activities (2023 - 2025) Analysis & Trends
Telomir Pharmaceuticals has reported Cash from Financing Activities for 3 years, with the latest figure at $1.2 million in Q4 2025.
- Quarterly Cash from Financing Activities rose 11.71% year-over-year to $1.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.7 million (up 52.34% YoY) and the FY2025 annual result came in at $9.7 million, up 53.25% from the prior year.
- Cash from Financing Activities fell to $1.2 million in Q4 2025 per TELO's latest filing, from $7.5 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $7.5 million in Q3 2025 and troughed at -$46909.0 in Q3 2024.
- A 3-year average of $1.9 million and a median of $1.1 million in 2023 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities sank 102.36% in 2024, then soared 16093.18% in 2025.
- Over 3 years, Cash from Financing Activities stood at $1.1 million in 2023, then slipped by 4.48% to $1.0 million in 2024, then grew by 11.71% to $1.2 million in 2025.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $1.2 million, $7.5 million, and $1.0 million for Q4 2025, Q3 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Telomir Pharmaceuticals | 69.05 Mn | 69.05 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.16 Mn |
| Dec 31, 2025 | 1.16 Mn |
| Sep 30, 2025 | 7.50 Mn |
| Sep 30, 2025 | 7.50 Mn |
| Dec 31, 2024 | 1.04 Mn |
| Dec 31, 2024 | 1.04 Mn |
| Sep 30, 2024 | -46,909.00 |
| Sep 30, 2024 | -46,909.00 |
| Jun 30, 2024 | 132,438.00 |
| Jun 30, 2024 | 132,438.00 |
| Mar 31, 2024 | 5.21 Mn |
| Mar 31, 2024 | 5.21 Mn |
| Dec 31, 2023 | 1.09 Mn |
| Dec 31, 2023 | 1.09 Mn |
| Sep 30, 2023 | 1.99 Mn |
| Sep 30, 2023 | 1.99 Mn |
| Jun 30, 2023 | 46,399.00 |
| Jun 30, 2023 | 46,399.00 |
| Mar 31, 2023 | 736,127.00 |
| Mar 31, 2023 | 736,127.00 |